European experience on oncological outcomes of patients with early-stage non-small cell lung cancer and any prior cancer following lobectomy or segmentectomy [0.03%]
欧洲早期非小细胞肺癌术前任何部位肿瘤患者 lobectomy 或段切术后预后的经验教训
Lukadi Joseph Lula,Rita Costa,Lin Huang et al.
Lukadi Joseph Lula et al.
Objectives: To assess the impact of lung resection extent on early-stage non-small cell lung cancer with a history of any cancer. Methods: ...
Multicenter Study
Lung cancer (Amsterdam, Netherlands). 2026 Jul:217:109410. DOI:10.1016/j.lungcan.2026.109410 2026
Real-world clinical characteristics and outcomes in patients with HER2-mutant non-small cell lung cancer (NSCLC) who received second-line treatment: A nationwide database analysis in Japan [0.03%]
接受二线治疗的HER2突变型非小细胞肺癌（NSCLC）患者的真实世界临床特征及预后：一项日本全国数据库分析
Yuji Uehara,Masachika Ikegami,Shinji Kohsaka et al.
Yuji Uehara et al.
Background: Although human epidermal growth factor receptor 2 (HER2)-targeted therapies have been approved for HER2-mutant NSCLC, real-world outcome data especially in the second-line setting remains limited. ...
Integrating chest CT-derived skeletal muscle index with SARC-F for sarcopenia screening in patients with lung cancer [0.03%]
结合胸部CT衍生的骨骼肌指数和SARC-F进行肺癌患者的肌少症筛查
Huiwen Weng,Yinghong Li,Lianyue Yang et al.
Huiwen Weng et al.
Aims: To evaluate and compare the diagnostic performance of thoracic computed tomography (CT)-derived skeletal muscle indexes (SMIs), used alone and combined with the SARC-F questionnaire, for identifying sarcopenia in lu...
Development of a clinical prediction model using digital device data for interstitial lung disease in patients with unresectable stage III non-small cell lung cancer treated with durvalumab [0.03%]
使用数字设备数据开发临床预测模型以预测不可切除III期非小细胞肺癌患者接受度伐卢单抗治疗后间质性肺病的发生
Satoshi Ikeda,Hirotsugu Kenmotsu,Ryo Koto et al.
Satoshi Ikeda et al.
Background: Early detection of interstitial lung disease including radiation pneumonitis (ILD/RP) is crucial in consolidative durvalumab therapy after chemoradiotherapy (CRT) in unresectable stage III non-small cell lung ...
Comparative efficacy of tarlatamab and second-line therapies in extensive-stage small cell lung cancer: A network meta-analysis [0.03%]
泰拉塔马布和广泛期小细胞肺癌二线疗法疗效的网络meta分析
Jessie Wang,Rumbidzai Takundwa,Hongbo Yang et al.
Jessie Wang et al.
Introduction: In the phase 3 DeLLphi-304 trial, tarlatamab demonstrated significant clinical benefit over second-line (2L) standard-of-care (SOC) chemotherapy options (topotecan, lurbinectedin, amrubicin) in patients with...
Cardiovascular adverse events in non-small cell lung cancer patients receiving osimertinib therapy: a systematic review and meta-analysis [0.03%]
奥希替尼治疗非小细胞肺癌患者心血管不良事件的系统评价和meta分析
Wei-He Liu,Yun-Jiu Cheng,Jin Kang et al.
Wei-He Liu et al.
Background and aims: The incidences and specific risk factors for cardiovascular adverse events (CVAEs) during osimertinib treatment remain uncertain. Met...
Real-world comparative effectiveness of sotorasib versus docetaxel monotherapy in second line and beyond for advanced or metastatic non-small cell lung cancer: A national database analysis from England [0.03%]
关于二至多线治疗晚期或转移性非小细胞肺癌患者使用索托雷塞与多西他赛单药治疗的现实世界有效性比较研究：来自英国国家数据库分析结果
Nadia Karim,Kellyn Arnold,Yvonne Summers et al.
Nadia Karim et al.
Purpose: To compare sotorasib versus docetaxel monotherapy real-world outcomes in second line and beyond (2 L+) for locally advanced or metastatic non-small cell lung cancer (NSCLC). ...
Comparison of protein-based and genetic prognostic markers in a large cohort of primary pulmonary and extrapulmonary small cell neuroendocrine carcinoma [0.03%]
基于蛋白质和基因的大细胞神经内分泌癌预后标志物的比较研究
Klára Pavlíčková,Jan Hojný,Nikola Hájková et al.
Klára Pavlíčková et al.
Small cell neuroendocrine carcinomas occur in both pulmonary (SCLC) and extrapulmonary sites (EP-SCNC). Although morphologically similar, they may differ biologically, but these differences are not well characterized. The aim of this study ...
Characteristics and clinical outcomes of a nationwide cohort of patients with small cell lung cancer following first-line treatment: Real-world evidence [0.03%]
一线治疗后小细胞肺癌全国队列的临床特征和结局：真实世界证据
Aylen Vanessa Ospina-Serrano,Manuel Cobo,Virginia Calvo et al.
Aylen Vanessa Ospina-Serrano et al.
Background: Patients with small cell lung cancer (SCLC) have an unfavorable prognosis. Our aim was to describe characteristics and clinical outcomes of a nationwide cohort of patients. ...
Circulating tumor DNA analysis in lung cancer: from molecular origins to analytical boundaries [0.03%]
肺癌的循环肿瘤DNA分析：从分子起源到分析界限
Jia-Tao Zhang,Bai-Xin Lin,Xin-Guang Zhao et al.
Jia-Tao Zhang et al.
Circulating tumor DNA (ctDNA) has revolutionized lung cancer management, yet its clinical sensitivity remains fundamentally limited by biological factors governing ctDNA release, clearance, and abundance. This review examines how these biol...